Merck 3Q 2026: Revenue $18.09B, Net income $5.07B, EPS $2.04— 10-Q Summary

What happened

Merck reported third-quarter 2026 revenue of $18.09B, up 4.7% from a year earlier, while net income fell 12.4% to $5.07B and diluted earnings per share, or EPS, fell 12.1% to $2.04. Oncology, cardiometabolic and animal health products led sales growth.

Confirmed

Global impact / market context

Revenue growth alongside falling net income and EPS means the company generated more sales but retained less profit overall and per share. If that pattern continues, earnings may not keep pace with sales, which can shape investor expectations for Merck’s financial performance.

Analyst inference

Sales growth was uneven: Keytruda and Winrevair increased, while Januvia/Janumet and vaccines declined. U.S. sales also received about $550M from purchase timing, which Merck expects to unwind, so that temporary boost may not support future revenue at the same level.

Analyst inference

What to watch

1. Check whether Merck’s next reported results show net income and EPS stabilizing or falling further despite revenue growth, as this would clarify the gap between sales and profit. Analyst inference
2. Watch for the expected unwind of about $550M in U.S. purchase-timing benefits, which could reduce reported sales compared with the quarter that included the boost. Confirmed
3. Track whether planned Lipfendra launches and new approvals or indication expansions contribute sales, while declines in Januvia/Janumet and vaccines continue to weigh on revenue. Analyst inference

Evidence

• Original source link unavailable